

Weekly New Drug Approvals

Jun. 24th 2024

1. pneumococcal 21-valent conjugate vaccine

FDA Approval Date: Jun 18th, 2024


Brand name: Capvaxive

Indication: Invasive streptococcal disease/
Pneumonia, Pneumococcal

Mechanism: Immunostimulants

Dosage form: Intramuscular injection

Company: Merck Sharp & Dohme LLC



Capvaxive works by inducing opsonophagocytic killing (the engulfment, by macrophages and other phagocytic cells like neutrophils) of bacteria. Capvaxive induces opsonophagocytic activity (OPA) against 22 *S. pneumoniae* serotypes (serotype 15B has a similar molecular structure to serotype 15C) using opsonization (an immune process where opsonins, such as antibodies, are used to tag foreign pathogens for elimination by phagocytes) to target the specific *S. pneumoniae* serotypes. Capvaxive protects against 8 serotypes not covered by other pneumococcal shots.



2. Golidocitinib

NMPA Approval Date: Jun 19th, 2024

Indication: Peripheral T-Cell Lymphoma

Mechanism: JAK1 inhibitors

Dosage form: Capsule

Company: Dizal Pharma

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/r PTCL patients, compared with existing treatment options.